Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertensionRajkumar Savai, Soni Savai Pullamsetti, Daniel Sedding et al.|Nature Medicine|2014Cited by 280
Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.Matthew J. Wieduwilt, Richard M. Stone, Katarzyna Jamieson et al.|Journal of Clinical Oncology|2023Cited by 49
S117: CHEMOTHERAPY-FREE TREATMENT WITH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB FOR OLDER ADULTS WITH NEWLY-DIAGNOSED, PH-NEGATIVE, CD22-POSITIVE, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: ALLIANCE A041703Matthew J. Wieduwilt, Richard M. Stone, Jun Yin et al.|HemaSphere|2023Cited by 13
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 ResultsMatthew J. Wieduwilt, Richard M. Stone, Jun Yin et al.|Journal of Clinical Oncology|2025Cited by 7
Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and survivalMatthew J. Wieduwilt, Richard M. Stone, Jun Yin et al.|Blood|2025Cited by 2